title: High throughput evaluation of gamma-H2AX.
abstract: The DNA double-strand break (DSB) is the primary lethal lesion after therapeutic radiation. Thus, the development of assays to detect and to quantitate these lesions could have broad preclinical and clinical impact. Phosphorylation of histone H2AX to form gamma-H2AX is a known marker for irradiation-induced DNA DSBs. However, the first generation assay involves the use of immunofluorescent staining of gamma-H2AX foci. This assay is time consuming, operator dependent and is not scalable for high throughput assay development. Thus, we sought to develop a new assay using a high throughput electrochemiluminescent platform from Mesoscale Discovery Systems to quantify gamma-H2AX levels. The results show that our assay utilizes significantly less time and labor, has greater intra-assay reproducibility and has a greater dynamic range of gamma-H2AX versus irradiation dose.
authors.affiliation: Radiation Oncology Branch, National Cancer Institute, National Cancer Institute, Bethesda, Maryland, USA. avondogd@mail.nih.gov
authors.forename: Dane
authors.initials: D
authors.lastname: Avondoglio
authors.forename: Tamalee
authors.initials: T
authors.lastname: Scott
authors.forename: Whoon Jong
authors.initials: WJ
authors.lastname: Kil
authors.forename: Mary
authors.initials: M
authors.lastname: Sproull
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Tofilon
authors.forename: Kevin
authors.initials: K
authors.lastname: Camphausen
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D053903:DNA Breaks, Double-Stranded / Q000528:radiation effects*; D004307:Dose-Response Relationship, Radiation; D055664:Electrochemical Techniques; D005455:Fluorescent Antibody Technique; D006657:Histones / Q000528:radiation effects*; D006801:Humans; D008163:Luminescent Measurements; D051379:Mice; D008819:Mice, Nude; D010766:Phosphorylation / Q000528:radiation effects; D011878:Radiotherapy / Q000009:adverse effects*
chemical_list: C468783:H2AX protein, human; D006657:Histones
references.citation: Mol Cancer Ther. 2006 Jun;5(6):1504-10
references.pmid: 16818509
references.citation: Mol Cell Biol. 2003 Aug;23(16):5706-15
references.pmid: 12897142
references.citation: J Clin Oncol. 2007 Sep 10;25(26):4051-6
references.pmid: 17827453
references.citation: Cancer Res. 2004 Jan 1;64(1):316-21
references.pmid: 14729640
references.citation: Radiat Res. 2002 Oct;158(4):486-92
references.pmid: 12236816
references.citation: Assay Drug Dev Technol. 2007 Jun;5(3):391-401
references.pmid: 17638539
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):931-8
references.pmid: 18245557
references.citation: J Biol Chem. 1998 Mar 6;273(10):5858-68
references.pmid: 9488723
references.citation: Int J Radiat Biol. 2003 May;79(5):351-8
references.pmid: 12943243
references.citation: Cancer Res. 2005 Aug 1;65(15):6967-75
references.pmid: 16061682
references.citation: Radiat Res. 2003 Sep;160(3):309-17
references.pmid: 12926989
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62
references.pmid: 12679524